Table 4. Pemetrexed-resistance mechanisms related to drug dynamics in NSCLC.
| Authors | Samples | Histology [case load] | Factors | Characteristics with pemetrexed resistance |
|---|---|---|---|---|
| Yang M et al. [2014] (68) | A549 cells | – | RFC | Downregulated |
| Adjei AA et al. [2010] (69) | Tissue | SCC [31]; non-SCC [117] | RFC genotype | SNP 2117C > T: CC, CT; SNP 9148C > A: CC, AA |
| Christoph DC et al. [2013] (39) | Tissue | Adenocarcinoma [156]; SCC [12]; LCC [12]; combined tumors [20]; others [7] | FR-α | Downregulated |
| Uemura T et al. [2010] (70) | PC9 cells | – | ABCC11; ABCC11 genotype | Upregulated; SNP 538G > A: GA, GG |
| Yang M et al. [2014] (68) | A549 cells | – | FPGS | Downregulated |
| Fukuda S et al. [2016] (71) | Tissue & PC6 cells | Adenocarcinoma [89]; LCC [4]; non-SCC [8] | FPGS; FPGS genotype | Downregulated; SNP 2572C > T: CT, TT |
| Adjei AA et al. [2010] (69) | Tissue | SCC [31]; non-SCC [117] | GGH genotype | SNP 1042C > T: TT |
SCC, squamous cell carcinoma; non-SCC, non-squamous cell carcinoma; LCC, large-cell carcinoma; RFC, reduced folate receptor; FR-α, folate receptor-α; ABCC11, ATP-binding cassette sub-family C member 11; FPGS, folypolyglutamate synthetase; GGH, γ-glutamyl hydrolase; SNP, single nucleotide polymorphism.